Focusing on immuno-dermatology and advancing vilobelimab and INF904 into registrational-phase trials could potentially open up new revenue streams for InflaRx. This strategic pivot to address specific unmet needs in dermatology is likely to be viewed positively by investors, as it demonstrates the company's commitment to leveraging its expertise in targeted areas of high demand. The advancement of these treatments into later stages of development increases the likelihood of successful commercialization, which could significantly impact the company's valuation and stock price in the short term.